Dicoumarol has been gaining interest in the cancer setting due to its action as an inhibitor of nicotinamide adenine dinucleotide phosphate (NAD(P)):(quinone acceptor) oxidoreductase 1 (NQO1), by competing with NAD(P)H at the pyridine nucleotide binding site [91]. Here, NQO1 is linked to cancer.